Fig. 4From: The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patientsClassification performance after including clinicopathological features into pCR classification models. Comparison of AUCs between combinations of the E2F4 signature, Oncotype DX, MammaPrint, and clinicopathological features in a ER-positive patients and b ER-negative patients. Error bars indicate standard deviation calculated by performing 10-fold cross-validation 100 timesBack to article page